Press release
Metastatic Prostate Cancer Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Pipeline Analysis | Tavanta Therapeutics, Cardiff Onco
Metastatic Prostate Cancer Pipeline Insight
Metastatic Prostate Cancer Pipeline constitutes 80+ key companies continuously working towards developing 85+ Metastatic Prostate Cancer treatment therapies, analyzes DelveInsight.
Metastatic Prostate Cancer Overview:
Metastatic prostate cancer represents an advanced form of the disease in which cancer cells spread from the prostate gland to other parts of the body, typically via the bloodstream or lymphatic system. This stage presents serious clinical challenges, as it can impact critical organs such as the bones, lymph nodes, liver, and lungs. Common symptoms include persistent bone pain (particularly in the lower back, hips, or ribs), urinary difficulties, erectile dysfunction, fatigue, unintended weight loss, and in severe cases, neurological issues caused by spinal cord compression.
Several factors contribute to the risk of developing metastatic prostate cancer, including age, family history, ethnicity, and genetic predisposition. Although the precise cause remains uncertain, the disease usually begins in the cells of the prostate and progresses over time. As it advances, the cancer often spreads to the bones, resulting in intense pain and serious skeletal complications.
Request for a detailed insights report on Metastatic Prostate Cancer pipeline insights [https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Metastatic Prostate Cancer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Prostate Cancer Therapeutics Market.
Key Takeaways from the Metastatic Prostate Cancer Pipeline Report
*
DelveInsight's Metastatic Prostate Cancer pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Metastatic Prostate Cancer treatment.
*
In September 2024, Ipsen reported that the Phase III CONTACT-02 trial of Cabometyx Registered and atezolizumab in mCRPC showed a minor, non-significant improvement in overall survival but achieved its progression-free survival (PFS) goal.
*
That same month, Foundation Medicine secured FDA approval for FoundationOne Registered CDx and Liquid CDx as companion diagnostics for Lynparza Registered in BRCA-mutated mCRPC.
*
In July 2024, the ARANOTE trial demonstrated that NUBEQA Registered combined with ADT significantly enhanced radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
*
Also in July 2024, the FDA granted fast-track status to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).
*
In June 2024, Kangpu Biopharmaceuticals received FDA approval to conduct a Phase II/III trial of KPG-121 in combination with Abiraterone for mCRPC.
*
In May 2024, Fusion Pharmaceuticals launched the Phase 2 AlphaBreak trial to evaluate FPI-2265 in mCRPC patients.
*
In April 2024, Astellas Pharma gained European approval for XTANDI Trademark in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).
*
That same month, FibroGen shared positive Phase 1 trial results for FG-3246 in mCRPC.
*
On November 16, 2023, the FDA approved enzalutamide (Xtandi) for high-risk biochemical recurrent non-metastatic castration-sensitive prostate cancer (nmCSPC).
*
Key Metastatic Prostate Cancer companies such as Tavanta Therapeutics, Cardiff Oncology, Oncternal Therapeutics, Valerio Therapeutics, ORIC Pharmaceuticals, Telix Pharmaceuticals (Innovations) Pty Limited, Orion Corporation, OncoC4, Inc., Bristol-Myers Squibb/Ono Pharmaceuticals, Janssen Research & Development, LLC, Merck Sharp & Dohme LLC, Modra Pharmaceuticals, Minneamrita Therapeutics LLC, AB Science, Cellbion Co., Ltd., Allarity Therapeutics, Janssen Research & Development, LLC, Hansoh BioMedical R&D Company, Jiangsu HengRui Medicine Co., Ltd., Hinova Pharmaceuticals Inc, ValiRx Plc, Epizyme, Inc., Astrazeneca, and others are evaluating new drugs for Metastatic Prostate Cancer to improve the treatment landscape.
*
Promising Metastatic Prostate Cancer pipeline therapies in various stages of development include TAVT-45, Onvansertib, ONCT-534, VIO-01, ORIC-944, and others.
Metastatic Prostate Cancer Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Metastatic Prostate Cancer Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Prostate Cancer treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Prostate Cancer market.
Download our free sample page report on Metastatic Prostate Cancer pipeline insights [https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Metastatic Prostate Cancer Emerging Drugs
*
TAVT-45: Tavanta Therapeutics
*
Onvansertib: Cardiff Oncology
*
ONCT-534: Oncternal Therapeutics
*
VIO-01: Valerio Therapeutics
*
ORIC-944: ORIC Pharmaceuticals
Metastatic Prostate Cancer Companies
Nearly 80 major companies are actively working on developing treatments for metastatic prostate cancer. Among these, Tavanta Therapeutics has a drug candidate that is at the most advanced stage prior to entering Phase III clinical trials.
DelveInsight's report covers around 85+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Metastatic Prostate Cancer Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Metastatic Prostate Cancer Therapies and Key Companies: Metastatic Prostate Cancer Clinical Trials and advancements [https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Metastatic Prostate Cancer Pipeline Therapeutic Assessment
- Metastatic Prostate Cancer Assessment by Product Type
- Metastatic Prostate Cancer By Stage
- Metastatic Prostate Cancer Assessment by Route of Administration
- Metastatic Prostate Cancer Assessment by Molecule Type
Download Metastatic Prostate Cancer Sample report to know in detail about the Metastatic Prostate Cancer treatment market @ Metastatic Prostate Cancer Therapeutic Assessment [https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Metastatic Prostate Cancer Current Treatment Patterns
4. Metastatic Prostate Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Metastatic Prostate Cancer Late-Stage Products (Phase-III)
7. Metastatic Prostate Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic Prostate Cancer Discontinued Products
13. Metastatic Prostate Cancer Product Profiles
14. Metastatic Prostate Cancer Key Companies
15. Metastatic Prostate Cancer Key Products
16. Dormant and Discontinued Products
17. Metastatic Prostate Cancer Unmet Needs
18. Metastatic Prostate Cancer Future Perspectives
19. Metastatic Prostate Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Metastatic Prostate Cancer Pipeline Reports Offerings [https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-prostate-cancer-clinical-trials-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-pipeline-analysis-tavanta-therapeutics-cardiff-onco]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Prostate Cancer Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Pipeline Analysis | Tavanta Therapeutics, Cardiff Onco here
News-ID: 4115020 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Metastatic
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth?
The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
